Author Archives: Natalie Themm
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
SALT LAKE CITY, March 30, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the twelve-month period ended December 31, 2021. Recent Business and Financial Updates In the first quarter of 2022, PolarityTE received approval from the U.S. […]
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital
The total capital represents the largest seed financing for life science startups in Utah’s history
Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s Disease
Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit.
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
Pfizer’s $7B bet delivers phase 3 success, advancing bid to establish new drug in ulcerative colitis Arena
Pfizer’s $6.7 billion bet on Arena Pharmaceuticals has delivered a phase 3 success.
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Recursion reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.
FierceBiotech recognizes Recursion as the #2 Biotech IPO of 2021!
FierceBiotech Special Report: The top 10 biotech IPOs of 2021
Co-Diagnostics Reports Full Year 2021 Financial Results
Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of HER2 negative high-risk early-stage breast cancer
